1II
3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1~{H}-benzimidazol-2-one
Created: | 2022-01-23 |
Last modified: | 2022-05-04 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 63 |
Chiral Atom Count | 0 |
Bond Count | 67 |
Aromatic Bond Count | 18 |
Chemical Component Summary | |
---|---|
Name | 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1~{H}-benzimidazol-2-one |
Systematic Name (OpenEye OEToolkits) | 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1~{H}-benzimidazol-2-one |
Formula | C28 H29 F2 N3 O |
Molecular Weight | 461.546 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.385 | Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5 |
SMILES | OpenEye OEToolkits | 2.0.7 | c1ccc2c(c1)NC(=O)N2C3CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F |
Canonical SMILES | CACTVS | 3.385 | Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5 |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | c1ccc2c(c1)NC(=O)N2C3CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F |
InChI | InChI | 1.03 | InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) |
InChIKey | InChI | 1.03 | YVUQSNJEYSNKRX-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank ID | DB01100 |
---|---|
Name | Pimozide |
Groups | approved |
Description | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) |
Synonyms |
|
Brand Names |
|
Indication | Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment. |
Categories |
|
ATC-Code | N05AG02 |
CAS number | 2062-78-4 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
D(2) dopamine receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | antagonist |
D(3) dopamine receptor | MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV... | unknown | antagonist |
Voltage-gated inwardly rectifying potassium channel KCNH2 | MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCE... | unknown | inhibitor |
Calmodulin | MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQ... | unknown | inhibitor |
Cytochrome P450 2D6 | MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1423 |
PubChem | 16362 |
ChEMBL | CHEMBL1423 |
ChEBI | CHEBI:8212 |